PepGen nabs $112.5m

PepGen Inc, a developer of oligonucleotide therapies for neuromuscular and neurologic diseases, has raised $112.5 million in financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this